Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin

Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORIN™ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare skin diseases. The newly granted patent No. 12,268,673 extends patent protection for QTORIN™ rapamycin into 2038 and covers its composition and methods of use, including its application for microcystic lymphatic malformations (microcystic LMs). QTORIN…

Palvella Secures New US Patent for Qtorin Rapamycin in Microcystic Lymphatic Malformations

Palvella has secured its 5th US patent for Qtorin rapamycin, extending intellectual property coverage to 2038 and advancing treatment for microcystic lymphatic malformations.